home / stock / idrsf / idrsf quote
Last: | $2.36 |
---|---|
Change Percent: | 100.0% |
Open: | $0 |
Close: | $2.36 |
High: | $0 |
Low: | $0 |
Volume: | 832 |
Last Trade Date Time: | 12/31/1969 07:00:00 pm |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$2.36 | $0 | $2.36 | $0 | $0 | 832 | 06-27-2024 |
$2.36 | $0 | $2.36 | $0 | $0 | 10,000 | 06-21-2024 |
$2.36 | $2.36 | $2.36 | $2.36 | $2.36 | 1,100 | 06-10-2024 |
$2.88 | $2.88 | $2.88 | $2.88 | $2.88 | 100 | 06-03-2024 |
$2.25 | $2.25 | $2.25 | $2.25 | $2.25 | 1,500 | 05-31-2024 |
$2.44 | $2.45 | $2.44 | $2.45 | $2.44 | 467 | 05-28-2024 |
$2.4 | $2.4 | $2.4 | $2.4 | $2.4 | 2,000 | 05-23-2024 |
$2.3 | $2.3 | $2.3 | $2.3 | $2.3 | 200 | 05-21-2024 |
$2.3 | $0 | $2.3 | $0 | $0 | 14,000 | 05-16-2024 |
$2.3 | $2.3 | $2.3 | $2.3 | $2.3 | 1,751 | 05-08-2024 |
$2.3 | $2.3 | $2.3 | $2.3 | $2.3 | 400 | 05-06-2024 |
$2.15 | $2.15 | $2.15 | $2.15 | $2.15 | 1,080 | 05-03-2024 |
$1.95 | $0 | $1.95 | $0 | $0 | 80 | 05-02-2024 |
$1.95 | $1.95 | $1.95 | $1.95 | $1.95 | 5,600 | 04-30-2024 |
$2.1 | $2.1 | $2.1 | $2.1 | $2.1 | 315 | 04-29-2024 |
$2.1 | $0 | $2.1 | $0 | $0 | 20 | 04-24-2024 |
$2.1 | $2.1 | $2.1 | $2.1 | $2.1 | 858 | 04-23-2024 |
$2.1 | $1.75 | $2.1 | $2.1 | $1.75 | 2,000 | 04-22-2024 |
$2.03 | $0 | $2.03 | $0 | $0 | 5,000 | 04-15-2024 |
$2.03 | $2.03 | $2.03 | $2.03 | $2.03 | 500 | 04-11-2024 |
News, Short Squeeze, Breakout and More Instantly...
Idorsia AG Company Name:
IDRSF Stock Symbol:
OTCMKTS Market:
Ad hoc announcement pursuant to Art. 53 LR Viatris and Idorsia will collaborate on the global development and commercialization of two Phase 3 assets, selatogrel and cenerimod. Idorsia to receive an upfront payment of USD 350 million, potential development and regulatory milestone pay...
Allschwil, Switzerland – November 3, 2023 Idorsia Ltd (SIX: IDIA) announced today that further data for aprocitentan, Idorsia’s investigational dual endothelin receptor antagonist for the treatment of patients with resistant hypertension, were presented as an oral presentati...
Allschwil, Switzerland – June 2 6 , 2023 Idorsia Ltd (SIX: IDIA) today announced that further data for aprocitentan, Idorsia’s investigational dual endothelin receptor antagonist evaluating the treatment of patients with resistant hypertension, were presented as ...